No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)

Background. The progressive phase of multiple sclerosis (MS) is characterized by an intrathecal (IT) compartmentalization of inflammation, involving B-cells within meningeal follicles, and resisting all the available immunosuppressive treatments. A new therapeutic paradigm may be to target this infl...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Multiple sclerosis international Ročník 2021; s. 1 - 7
Hlavní autori: Bonnan, Mickael, Ferrari, Sylvie, Courtade, Henri, Money, Paul, Desblache, Pauline, Barroso, Bruno, Debeugny, Stéphane
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Egypt Hindawi 2021
John Wiley & Sons, Inc
Predmet:
Clinical trials
Dexchlorpheniramine
Drug dosages
Health aspects
Immunotherapy
Inflammation
Monoclonal antibodies
Multiple sclerosis
Patients
Statistical analysis
France
ISSN:2090-2654, 2090-2662
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background. The progressive phase of multiple sclerosis (MS) is characterized by an intrathecal (IT) compartmentalization of inflammation, involving B-cells within meningeal follicles, and resisting all the available immunosuppressive treatments. A new therapeutic paradigm may be to target this inflammation by injecting immunosuppressive drugs inside the central nervous system compartment. Methods. We designed a single-center, open-label, randomized, controlled, phase II study designed to evaluate the safety and efficacy of IT rituximab in progressive MS (EFFRITE trial; ClinicalTrial Registration NCT02545959). Patients were randomized into three arms (1 : 1 : 1): control group, IT rituximab (20 mg, IT) group, and intravenous+IT (IV+IT) group. The main outcome was a change in levels of CSF biomarkers of inflammation (osteopontin). Secondary outcomes were changes in levels of CSF biomarkers of axonal loss (neurofilament light chain) and clinical and MRI changes. Results. Ten patients were included (2 : 4 : 4). No adverse event occurred. OPN level remained stable in CSF at each time point, whereas NFL had slightly decreased (-8.7%) at day 21 (p=0.02). Clinical parameters remained stable and leptomeningeal enhancements remained unchanged. Conclusion. Clinical outcome and biomarkers of inflammation were not dramatically modified after IT injection of rituximab, probably due to its limited efficiency in CSF. Drug issues for future studies are discussed.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Academic Editor: Antonio Bertolotto
ISSN:2090-2654
2090-2662
DOI:10.1155/2021/8813498